How Much Can You Save?
Speak With a Copay Assistance Specialist
We accept Medicare, multi-state Medicaid, Medi-Cal, Blue Shield, and most private insurances.
Get Started in Minutes
How Ogivri Copay Assistance Works
1 – Check Your Coverage/Benefits Verification
Our team of expert billers finds the best avenues of coverage that minimize out-of-pocket costs.
2 – Transfer Prescription to AmeriPharma
We process your prescription by working with your previous pharmacy or prescriber, making the transition quick and easy.
3 – Prior Authorization
Our team of specialists obtains approval from your insurance companies within 24 to 72 hours.
4 – Copay Assistance & Financial Aid
We secure financial aid and decrease copays, out-of-pocket expenses, and high deductibles. To date, AmeriPharma Specialty Care has secured $55 million in financial assistance for our patients.
5 – Nursing Care Coordination
AmeriPharma puts your schedule and home environment first when scheduling and coordinating one of our specialized nurses for your in-home infusions.
6 – Delivery Coordination
Medications are always delivered in strict compliance with the specific requirements for immune globulin shipping. Next-day and overnight cold-chain deliveries are coordinated around your schedule.
Speak With a Specialist
We accept Medicare, multi-state Medicaid, Medi-Cal, Blue Shield, and most private insurances. Call us to find out more about your coverage.
What is Ogivri?
Ogivri is a prescription medication used to treat some kinds of cancer. It is a type of medication called monoclonal antibodies, similar to antibodies that our bodies make to protect us when an unwanted substance enters our bodies. In the case of Ogivri, the monoclonal antibody is designed to bind to the extracellular domain of the human epidermal growth factor receptor 2 protein (HER-2). This then suppresses the rapid reproduction of cells that overexpress HER-2 protein (cancer cells).
The generic name of Ogivri is trastuzumab-dkst; it is manufactured by Mylan and was first approved in 2017 as a biosimilar to Herceptin (trastuzumab).
Ogivri is available as 150 mg and 420 mg single-use vials.
Schedule a Consultation
We accept Medicare, multi-state Medicaid, Medi-Cal, Blue Shield, and most private insurances. Call us to find out more about your coverage.
What Is Ogivri Used To Treat?
Ogivri is used to treat the following:
Breast cancer, HER2
Ogivri is used as an adjuvant treatment, and as part of a treatment regimen consisting of:
- Doxorubicin, cyclophosphamide, and either paclitaxel or docetaxel
- Docetaxel and carboplatin
- Ogivri as a single agent following multimodality anthracycline-based therapy
Metastatic Breast Cancer, HER2+
Ogivri is used as a first-line treatment, either used:
- In combination with paclitaxel
- As a single agent in patients who have received one or more chemotherapy regimens for metastatic disease
Metastatic Gastric Cancer, HER2+
Ogivri is used for gastric or gastroesophageal junction adenocarcinoma in patients who have not received prior treatment for metastatic disease. It is used in combination with cisplatin and either:
- Capecitabine
- 5-fluorouracil
Copay and Financial Assistance
AmeriPharma Specialty Care alleviates financial burdens for patients and their families
Advanced software locates funding sources to match you with top-dollar foundation programs
One of our copay assistance specialists will assist with the application process
Automatic updates will be sent to you and your physician on the status of the funding
Speak With a Specialist
We accept Medicare, multi-state Medicaid, Medi-Cal, Blue Shield, and most private insurances. Call us to find out more about your coverage.
Ogivri Side Effects
- Decreased ejection fraction of the left ventricle of the heart
- Rash
- Abdominal pain
- Loss of appetite
- Diarrhea
- Nausea
- Vomiting
- Infection
- Chills
- Dizziness
- Headache
- Difficulty falling asleep
- Pain
- Weakness
- Back pain
- Cough
- Shortness of breath
- Pain in the throat
- Stuffy nose
- Fever
- Infusion-related reaction
- Arrhythmia of the heart
- Heart failure
- Swelling
- High blood pressure
- Heart palpitations
- Fast heart rate
- Skin acne
- Nail deformity
- Itching
- Constipation
- Indigestion
- Urinary tract infection
- Anemia
- Low white blood cell count
- Allergic reaction
- Flu
- Herpes simplex infection
- Depression
- Nerve damage
- Tingling or prickling, “pins-and-needles” sensation
- Weakness, numbness, and pain in the hands and feet
- Stiffness of the joints
- Muscle spasm
- Muscle pain
- Bone pain
- Nosebleed
- Flu-like symptoms
- Common cold
- Sinus infection
- Upper respiratory tract infection
Schedule a Consultation
We accept Medicare, multi-state Medicaid, Medi-Cal, Blue Shield, and most private insurances. Call us to find out more about your coverage.
Dosing Information
Ogivri is administered as an intravenous (IV) infusion given as a loading dose followed by maintenance doses, and depending on the indication to be treated, the doses are calculated as follows:
- Breast cancer, adjuvant treatment, HER2+:
- With concurrent paclitaxel or docetaxel:
- Initial loading dose, IV: 4 mg/kg infused over 90 minutes
- Maintenance dose, IV: 2 mg/kg infused over 30 minutes weekly for a total of 12 weeks, followed by 6 mg/kg infused over 30 to 90 minutes 1 week later (when concurrent chemotherapy completed) and every 3 weeks thereafter for a total therapy duration of 52 weeks.
- With concurrent docetaxel/carboplatin:
- Initial loading dose, IV: 4 mg/kg infused over 90 minutes
- Maintenance dose, IV: 2 mg/kg infused over 30 minutes weekly for a total of 18 weeks, followed by 6 mg/kg infused over 30 to 90 minutes 1 week later (when concurrent chemotherapy completed) and every 3 weeks thereafter for a total therapy duration of 52 weeks.
- Following completion of multimodality anthracycline-based chemotherapy:
- Initial loading dose, IV: 8 mg/kg infused over 90 minutes
- Maintenance dose, IV: 6 mg/kg infused over 30 to 90 minutes every 3 weeks for a total therapy duration of 52 weeks.
- With concurrent paclitaxel or docetaxel:
- Metastatic Breast Cancer, Her2+ (Either as a single agent or in combination with paclitaxel):
- Initial loading dose, IV: 4 mg/kg infused over 90 minutes
- Maintenance dose, IV: 2 mg/kg infused over 30 minutes weekly until disease progression.
- Metastatic Gastric Cancer, HER2+ (In combination with cisplatin and either capecitabine or fluorouracil for 6 cycles followed by trastuzumab monotherapy):
- Initial loading dose, IV: 8 mg/kg infused over 90 minutes
- Maintenance dose, IV: 6 mg/kg infused over 30 to 90 minutes every 3 weeks until disease progression.
Ogivri vials are first reconstituted with sterile water for injection, and then the calculated dose is further diluted in normal saline for infusion.